half
acut
ill
specif
antivir
therapi
develop
respiratori
virus
thought
caus
urti
pharmacolog
action
glycyrrhizin
shown
produc
antiinflammatori
activ
modul
immun
system
inhibit
viru
growth
inactiv
virus
object
aim
studi
assess
toler
efficaci
cost
glycyrrhizin
improv
sever
durat
sign
symptom
urti
primari
end
point
toler
secondari
end
point
includ
improv
sign
symptom
urti
cost
upper
respiratori
tract
infect
urti
common
human
diseas
account
least
half
acut
ill
estim
two
third
three
fourth
urti
caus
respiratori
virus
although
therapi
develop
rhinovirus
influenza
virus
specif
antivir
therapi
develop
respiratori
virus
pharmacolog
action
glycyrrhizin
activ
compon
licoric
root
shown
produc
antiinflammatori
activ
modul
immun
system
inhibit
viru
growth
inactiv
virus
glycyrrhizin
also
found
inhibit
viru
growth
mice
infect
influenza
virus
improv
outcom
glycyrrhizin
typic
use
treat
chronic
hepat
allerg
dermat
urticaria
japan
occasion
use
treat
urti
without
prospect
random
doubleblind
control
studi
method
aim
studi
assess
efficaci
glycyrrhizin
improv
sign
symptom
urti
use
medlin
search
englishlanguag
articl
key
term
influenza
cold
upper
respiratori
tract
infect
glycyrrhizin
year
identifi
articl
topic
prospect
random
doubleblind
control
parallelgroup
alternateday
treatment
assign
studi
conduct
selfdefens
forc
sdf
etajima
hospit
hiroshima
japan
protocol
approv
human
investig
committe
hospit
member
japanes
maritim
sdf
age
urti
treat
januari
may
elig
patient
fulfil
follow
criteria
admit
hospit
first
arriv
day
outpati
fever
bodi
temperatur
sign
symptom
urti
headach
sore
throat
rhinorrhea
pharyng
receiv
antibiot
oseltamivir
phosphat
obtain
written
inform
consent
patient
studi
pregnant
possibl
pregnant
breastfeed
women
exclud
studi
chest
radiographi
detect
pneumonia
cultur
pharyng
swab
assess
bacteri
pathogen
blood
chemistri
perform
technician
patient
admiss
second
blood
chemistri
perform
second
hospit
day
patient
admit
consecut
day
admit
even
day
receiv
iv
drip
infus
ml
glycyrrhizin
ml
lactat
ringer
solut
daili
hospit
glycyrrhizin
group
patient
admit
odd
day
receiv
iv
drip
infus
mld
lactat
ringer
solut
without
glycyrrhizin
hospit
control
group
infus
prepar
hospit
pharmaci
label
ident
maintain
blind
patient
also
treat
pl
shionogi
co
ltd
osaka
japan
gd
mouth
g
pl
contain
salicyl
amid
mg
acetaminophen
mg
caffein
mg
promethazin
methylen
disalicyl
mg
andor
dextromethorphan
hydrobromid
mg
povidoneiodin
disinfect
oral
caviti
urti
sign
symptom
subsid
suppositori
diclofenac
sodium
mg
provid
patient
bodi
temperatur
exceed
studi
medic
administ
nurs
treat
physician
chang
medic
regimen
includ
pl
dextromethorphan
hydrobromid
loxoprofen
sodium
mefenam
acid
diclofenac
sodium
tipepidin
hybenz
andor
ibuprofen
need
studi
patient
discharg
bodi
temperatur
measur
time
day
nurs
sign
symptom
improv
suffici
allow
return
militari
duti
primari
end
point
toler
secondari
end
point
includ
improv
sign
symptom
urti
cost
toler
assess
result
laboratori
analysi
patient
interview
physician
hospit
calcul
direct
medic
cost
hospit
made
payer
perspect
base
social
insur
medic
fee
tabl
japan
betweengroup
differ
age
sex
bodi
temperatur
admiss
durat
hospit
maximum
bodi
temperatur
hour
admiss
blood
chemistri
includ
leukocyt
count
creactiv
protein
crp
level
find
chest
radiographi
result
cultur
pharyng
swab
cost
treatment
incid
advers
effect
ae
analyz
use
unpair
student
test
chisquar
test
appropri
difficult
make
quantit
analysi
sign
symptom
urti
compar
maximum
bodi
temperatur
hour
admiss
durat
hospit
stay
patient
could
discharg
bodi
temperatur
group
p
defin
statist
signific
statview
softwar
version
sa
institut
inc
cari
north
carolina
use
statist
analysi
total
consecut
patient
enrol
men
women
mean
sd
age
year
tabl
grew
pathogen
differ
signific
find
influenc
therapi
hospit
obtain
discharg
ae
report
either
group
mean
sem
cost
treatment
significantli
lower
glycyrrhizin
group
control
group
vs
p
tabl
ii
present
studi
glycyrrhizin
therapi
benefit
patient
urti
shorten
durat
hospit
decreas
cost
treatment
compar
control
although
signific
differ
frequenc
use
antipyret
drug
found
group
result
indic
lower
mean
bodi
temperatur
shorter
durat
hospit
glycyrrhizin
group
thu
glycyrrhizin
may
effect
decreas
sign
symptom
urti
includ
headach
sore
throat
rhinorrhea
pharyng
symptom
assess
temperatur
measur
treatment
outcom
studi
mean
differ
crp
level
first
second
hospit
day
glycyrrhizin
group
significantli
higher
control
group
crp
level
may
reflect
sever
infect
higher
crp
level
glycyrrhizin
group
suggest
sever
infect
control
group
despit
lower
mean
bodi
temperatur
shorter
durat
hospit
shown
glycyrrhizin
group
result
show
glycyrrhizin
therapi
may
benefici
patient
urti
although
primari
use
japan
chronic
hepat
c
viru
hcv
dermat
glycyrrhizin
also
use
treat
human
immunodefici
infrequ
ae
increas
blood
pressur
hypokalemia
report
patient
sever
month
glycyrrhizin
hcv
treatment
howev
studi
glycyrrhizin
use
short
time
ae
report
patient
studi
admit
sdf
etajima
hospit
give
us
advantag
abl
obtain
physiolog
laboratori
data
duti
militari
life
stress
soldier
poor
health
must
isol
allow
rest
soldier
hous
area
chose
hospit
rest
accordingli
result
studi
interpret
caution
due
higher
cost
shorter
durat
ill
would
found
typic
clinic
practic
due
hospit
patient
small
sampl
size
human
studi
warrant
verifi
result
studi
hospit
patient
urti
glycyrrhizin
therapi
associ
shorter
hospit
lowergrad
fever
lower
cost
therapi
compar
control
show
may
benefici
patient
urti
